nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitotane—FDX1—saliva-secreting gland—thyroid cancer	0.0338	0.215	CbGeAlD
Mitotane—FDX1—trachea—thyroid cancer	0.0261	0.166	CbGeAlD
Mitotane—FDX1—thyroid gland—thyroid cancer	0.0206	0.131	CbGeAlD
Mitotane—Balance disorder—Vandetanib—thyroid cancer	0.0204	0.028	CcSEcCtD
Mitotane—Mucosal inflammation—Vandetanib—thyroid cancer	0.0201	0.0277	CcSEcCtD
Mitotane—FDX1—head—thyroid cancer	0.0183	0.117	CbGeAlD
Mitotane—Hypothyroidism—Vandetanib—thyroid cancer	0.0173	0.0239	CcSEcCtD
Mitotane—Gastrointestinal toxicity—Epirubicin—thyroid cancer	0.0169	0.0233	CcSEcCtD
Mitotane—FDX1—Endogenous sterols—RXRA—thyroid cancer	0.0165	0.142	CbGpPWpGaD
Mitotane—SHBG—neck—thyroid cancer	0.0158	0.101	CbGeAlD
Mitotane—Gastrointestinal toxicity—Doxorubicin—thyroid cancer	0.0156	0.0215	CcSEcCtD
Mitotane—Fungal infection—Vandetanib—thyroid cancer	0.0144	0.0198	CcSEcCtD
Mitotane—Cystitis haemorrhagic—Epirubicin—thyroid cancer	0.0138	0.019	CcSEcCtD
Mitotane—Mucosal inflammation—Sorafenib—thyroid cancer	0.0136	0.0187	CcSEcCtD
Mitotane—Endocrine disorder—Vandetanib—thyroid cancer	0.0134	0.0185	CcSEcCtD
Mitotane—FDX1—lymph node—thyroid cancer	0.0128	0.0816	CbGeAlD
Mitotane—Cystitis haemorrhagic—Doxorubicin—thyroid cancer	0.0128	0.0176	CcSEcCtD
Mitotane—Proteinuria—Vandetanib—thyroid cancer	0.0127	0.0174	CcSEcCtD
Mitotane—Protein urine present—Vandetanib—thyroid cancer	0.0125	0.0172	CcSEcCtD
Mitotane—Hypothyroidism—Sorafenib—thyroid cancer	0.0117	0.0161	CcSEcCtD
Mitotane—Cataract—Vandetanib—thyroid cancer	0.0117	0.0161	CcSEcCtD
Mitotane—CYP11A1—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.0113	0.0969	CbGpPWpGaD
Mitotane—Neoplasm—Vandetanib—thyroid cancer	0.0101	0.0139	CcSEcCtD
Mitotane—Endocrine disorder—Sorafenib—thyroid cancer	0.00906	0.0125	CcSEcCtD
Mitotane—Proteinuria—Sorafenib—thyroid cancer	0.00855	0.0118	CcSEcCtD
Mitotane—Polyneuropathy—Epirubicin—thyroid cancer	0.00851	0.0117	CcSEcCtD
Mitotane—Protein urine present—Sorafenib—thyroid cancer	0.00843	0.0116	CcSEcCtD
Mitotane—CYP11A1—head—thyroid cancer	0.00832	0.053	CbGeAlD
Mitotane—Lethargy—Vandetanib—thyroid cancer	0.00825	0.0114	CcSEcCtD
Mitotane—SERPINA6—head—thyroid cancer	0.00791	0.0504	CbGeAlD
Mitotane—Polyneuropathy—Doxorubicin—thyroid cancer	0.00788	0.0108	CcSEcCtD
Mitotane—FDX1—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00768	0.066	CbGpPWpGaD
Mitotane—SHBG—thyroid gland—thyroid cancer	0.00752	0.0478	CbGeAlD
Mitotane—Neoplasm—Sorafenib—thyroid cancer	0.00679	0.00935	CcSEcCtD
Mitotane—Gynaecomastia—Sorafenib—thyroid cancer	0.00672	0.00925	CcSEcCtD
Mitotane—Neutropenia—Vandetanib—thyroid cancer	0.00653	0.00899	CcSEcCtD
Mitotane—FDX1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00623	0.0535	CbGpPWpGaD
Mitotane—Infestation—Vandetanib—thyroid cancer	0.00623	0.00857	CcSEcCtD
Mitotane—Infestation NOS—Vandetanib—thyroid cancer	0.00623	0.00857	CcSEcCtD
Mitotane—Haematuria—Vandetanib—thyroid cancer	0.00594	0.00817	CcSEcCtD
Mitotane—CYP11B1—Endogenous sterols—RXRA—thyroid cancer	0.0059	0.0506	CbGpPWpGaD
Mitotane—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00589	0.00811	CcSEcCtD
Mitotane—CYP11A1—lymph node—thyroid cancer	0.00583	0.0371	CbGeAlD
Mitotane—Urinary tract disorder—Vandetanib—thyroid cancer	0.00552	0.0076	CcSEcCtD
Mitotane—Urethral disorder—Vandetanib—thyroid cancer	0.00548	0.00754	CcSEcCtD
Mitotane—Visual impairment—Vandetanib—thyroid cancer	0.00539	0.00742	CcSEcCtD
Mitotane—Eye disorder—Vandetanib—thyroid cancer	0.00522	0.00719	CcSEcCtD
Mitotane—Angiopathy—Vandetanib—thyroid cancer	0.00507	0.00698	CcSEcCtD
Mitotane—CYP11A1—Endogenous sterols—RXRA—thyroid cancer	0.00504	0.0433	CbGpPWpGaD
Mitotane—Mucosal inflammation—Epirubicin—thyroid cancer	0.00501	0.0069	CcSEcCtD
Mitotane—Breast disorder—Sorafenib—thyroid cancer	0.00493	0.00678	CcSEcCtD
Mitotane—Mental disorder—Vandetanib—thyroid cancer	0.0049	0.00674	CcSEcCtD
Mitotane—Malnutrition—Vandetanib—thyroid cancer	0.00487	0.0067	CcSEcCtD
Mitotane—Dysgeusia—Vandetanib—thyroid cancer	0.00477	0.00656	CcSEcCtD
Mitotane—Mucosal inflammation—Doxorubicin—thyroid cancer	0.00464	0.00638	CcSEcCtD
Mitotane—Vision blurred—Vandetanib—thyroid cancer	0.00459	0.00631	CcSEcCtD
Mitotane—Tremor—Vandetanib—thyroid cancer	0.00456	0.00628	CcSEcCtD
Mitotane—Myasthenia—Epirubicin—thyroid cancer	0.00441	0.00608	CcSEcCtD
Mitotane—Neutropenia—Sorafenib—thyroid cancer	0.00441	0.00606	CcSEcCtD
Mitotane—Hypertension—Vandetanib—thyroid cancer	0.0042	0.00578	CcSEcCtD
Mitotane—Infestation NOS—Sorafenib—thyroid cancer	0.0042	0.00578	CcSEcCtD
Mitotane—Infestation—Sorafenib—thyroid cancer	0.0042	0.00578	CcSEcCtD
Mitotane—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00411	0.00566	CcSEcCtD
Mitotane—Myasthenia—Doxorubicin—thyroid cancer	0.00409	0.00562	CcSEcCtD
Mitotane—CYP11B1—Metapathway biotransformation—CHST14—thyroid cancer	0.00399	0.0343	CbGpPWpGaD
Mitotane—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00397	0.00547	CcSEcCtD
Mitotane—Infection—Vandetanib—thyroid cancer	0.00395	0.00543	CcSEcCtD
Mitotane—Nervous system disorder—Vandetanib—thyroid cancer	0.00389	0.00536	CcSEcCtD
Mitotane—Thrombocytopenia—Vandetanib—thyroid cancer	0.00389	0.00535	CcSEcCtD
Mitotane—Skin disorder—Vandetanib—thyroid cancer	0.00386	0.00531	CcSEcCtD
Mitotane—Dermatitis atopic—Epirubicin—thyroid cancer	0.00375	0.00516	CcSEcCtD
Mitotane—Urinary tract disorder—Sorafenib—thyroid cancer	0.00372	0.00513	CcSEcCtD
Mitotane—Albuminuria—Epirubicin—thyroid cancer	0.00372	0.00512	CcSEcCtD
Mitotane—Connective tissue disorder—Sorafenib—thyroid cancer	0.00371	0.0051	CcSEcCtD
Mitotane—Urethral disorder—Sorafenib—thyroid cancer	0.0037	0.00509	CcSEcCtD
Mitotane—Fungal infection—Epirubicin—thyroid cancer	0.00359	0.00495	CcSEcCtD
Mitotane—Paraesthesia—Vandetanib—thyroid cancer	0.00357	0.00491	CcSEcCtD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00352	0.0302	CbGpPWpGaD
Mitotane—Flushing—Sorafenib—thyroid cancer	0.0035	0.00482	CcSEcCtD
Mitotane—Dyspepsia—Vandetanib—thyroid cancer	0.0035	0.00481	CcSEcCtD
Mitotane—Dermatitis atopic—Doxorubicin—thyroid cancer	0.00347	0.00478	CcSEcCtD
Mitotane—Decreased appetite—Vandetanib—thyroid cancer	0.00345	0.00475	CcSEcCtD
Mitotane—Albuminuria—Doxorubicin—thyroid cancer	0.00344	0.00473	CcSEcCtD
Mitotane—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00343	0.00472	CcSEcCtD
Mitotane—Angiopathy—Sorafenib—thyroid cancer	0.00342	0.00471	CcSEcCtD
Mitotane—CYP11A1—Metapathway biotransformation—CHST14—thyroid cancer	0.00342	0.0293	CbGpPWpGaD
Mitotane—Pain—Vandetanib—thyroid cancer	0.0034	0.00468	CcSEcCtD
Mitotane—Fungal infection—Doxorubicin—thyroid cancer	0.00333	0.00458	CcSEcCtD
Mitotane—FDX1—Biological oxidations—RXRA—thyroid cancer	0.00331	0.0284	CbGpPWpGaD
Mitotane—Mental disorder—Sorafenib—thyroid cancer	0.0033	0.00455	CcSEcCtD
Mitotane—Liver injury—Epirubicin—thyroid cancer	0.0033	0.00454	CcSEcCtD
Mitotane—Malnutrition—Sorafenib—thyroid cancer	0.00328	0.00452	CcSEcCtD
Mitotane—Dysgeusia—Sorafenib—thyroid cancer	0.00321	0.00442	CcSEcCtD
Mitotane—Body temperature increased—Vandetanib—thyroid cancer	0.00314	0.00432	CcSEcCtD
Mitotane—Liver injury—Doxorubicin—thyroid cancer	0.00305	0.0042	CcSEcCtD
Mitotane—Anaemia—Sorafenib—thyroid cancer	0.00303	0.00418	CcSEcCtD
Mitotane—Dyskinesia—Epirubicin—thyroid cancer	0.00295	0.00406	CcSEcCtD
Mitotane—Dysarthria—Epirubicin—thyroid cancer	0.00293	0.00404	CcSEcCtD
Mitotane—Asthenia—Vandetanib—thyroid cancer	0.00285	0.00392	CcSEcCtD
Mitotane—Hypertension—Sorafenib—thyroid cancer	0.00283	0.0039	CcSEcCtD
Mitotane—SHBG—Nongenotropic Androgen signaling—HRAS—thyroid cancer	0.00279	0.024	CbGpPWpGaD
Mitotane—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00278	0.00382	CcSEcCtD
Mitotane—Hepatocellular injury—Epirubicin—thyroid cancer	0.00278	0.00382	CcSEcCtD
Mitotane—CYP11B1—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00274	0.0235	CbGpPWpGaD
Mitotane—Dyskinesia—Doxorubicin—thyroid cancer	0.00273	0.00376	CcSEcCtD
Mitotane—Diarrhoea—Vandetanib—thyroid cancer	0.00272	0.00374	CcSEcCtD
Mitotane—Dysarthria—Doxorubicin—thyroid cancer	0.00271	0.00374	CcSEcCtD
Mitotane—Salivary hypersecretion—Epirubicin—thyroid cancer	0.0027	0.00371	CcSEcCtD
Mitotane—Infection—Sorafenib—thyroid cancer	0.00266	0.00366	CcSEcCtD
Mitotane—Shock—Sorafenib—thyroid cancer	0.00264	0.00363	CcSEcCtD
Mitotane—Nervous system disorder—Sorafenib—thyroid cancer	0.00263	0.00362	CcSEcCtD
Mitotane—Dizziness—Vandetanib—thyroid cancer	0.00263	0.00362	CcSEcCtD
Mitotane—Thrombocytopenia—Sorafenib—thyroid cancer	0.00262	0.00361	CcSEcCtD
Mitotane—Skin disorder—Sorafenib—thyroid cancer	0.0026	0.00358	CcSEcCtD
Mitotane—Hepatocellular injury—Doxorubicin—thyroid cancer	0.00257	0.00353	CcSEcCtD
Mitotane—Anorexia—Sorafenib—thyroid cancer	0.00255	0.00352	CcSEcCtD
Mitotane—Vomiting—Vandetanib—thyroid cancer	0.00253	0.00348	CcSEcCtD
Mitotane—Neoplasm—Epirubicin—thyroid cancer	0.00251	0.00345	CcSEcCtD
Mitotane—Rash—Vandetanib—thyroid cancer	0.0025	0.00345	CcSEcCtD
Mitotane—Dermatitis—Vandetanib—thyroid cancer	0.0025	0.00344	CcSEcCtD
Mitotane—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.00249	0.00343	CcSEcCtD
Mitotane—Headache—Vandetanib—thyroid cancer	0.00249	0.00342	CcSEcCtD
Mitotane—SHBG—Nongenotropic Androgen signaling—AKT1—thyroid cancer	0.00247	0.0212	CbGpPWpGaD
Mitotane—FDX1—Metabolism—MINPP1—thyroid cancer	0.00243	0.0209	CbGpPWpGaD
Mitotane—Mental disability—Epirubicin—thyroid cancer	0.00241	0.00331	CcSEcCtD
Mitotane—Nausea—Vandetanib—thyroid cancer	0.00236	0.00325	CcSEcCtD
Mitotane—Dyspepsia—Sorafenib—thyroid cancer	0.00236	0.00325	CcSEcCtD
Mitotane—CYP11A1—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00234	0.0201	CbGpPWpGaD
Mitotane—Decreased appetite—Sorafenib—thyroid cancer	0.00233	0.00321	CcSEcCtD
Mitotane—Neoplasm—Doxorubicin—thyroid cancer	0.00232	0.0032	CcSEcCtD
Mitotane—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00231	0.00318	CcSEcCtD
Mitotane—Pain—Sorafenib—thyroid cancer	0.00229	0.00315	CcSEcCtD
Mitotane—Mental disability—Doxorubicin—thyroid cancer	0.00223	0.00307	CcSEcCtD
Mitotane—CYP11B1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00222	0.0191	CbGpPWpGaD
Mitotane—Body temperature increased—Sorafenib—thyroid cancer	0.00212	0.00292	CcSEcCtD
Mitotane—FDX1—Metabolism—NDUFA13—thyroid cancer	0.00207	0.0177	CbGpPWpGaD
Mitotane—Lethargy—Epirubicin—thyroid cancer	0.00206	0.00283	CcSEcCtD
Mitotane—CYP11A1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.00203	0.0174	CbGpPWpGaD
Mitotane—Osteoarthritis—Epirubicin—thyroid cancer	0.00201	0.00277	CcSEcCtD
Mitotane—Diplopia—Epirubicin—thyroid cancer	0.00201	0.00277	CcSEcCtD
Mitotane—Hypersensitivity—Sorafenib—thyroid cancer	0.00197	0.00272	CcSEcCtD
Mitotane—FDX1—Metabolism—CHST14—thyroid cancer	0.00194	0.0167	CbGpPWpGaD
Mitotane—Asthenia—Sorafenib—thyroid cancer	0.00192	0.00265	CcSEcCtD
Mitotane—Lethargy—Doxorubicin—thyroid cancer	0.0019	0.00262	CcSEcCtD
Mitotane—CYP11A1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.0019	0.0163	CbGpPWpGaD
Mitotane—Ataxia—Epirubicin—thyroid cancer	0.00189	0.00261	CcSEcCtD
Mitotane—Osteoarthritis—Doxorubicin—thyroid cancer	0.00186	0.00257	CcSEcCtD
Mitotane—Diplopia—Doxorubicin—thyroid cancer	0.00186	0.00257	CcSEcCtD
Mitotane—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00184	0.00253	CcSEcCtD
Mitotane—Diarrhoea—Sorafenib—thyroid cancer	0.00183	0.00252	CcSEcCtD
Mitotane—Breast disorder—Epirubicin—thyroid cancer	0.00182	0.00251	CcSEcCtD
Mitotane—Muscular weakness—Epirubicin—thyroid cancer	0.00178	0.00245	CcSEcCtD
Mitotane—Dizziness—Sorafenib—thyroid cancer	0.00177	0.00244	CcSEcCtD
Mitotane—Ataxia—Doxorubicin—thyroid cancer	0.00175	0.00241	CcSEcCtD
Mitotane—Vomiting—Sorafenib—thyroid cancer	0.0017	0.00234	CcSEcCtD
Mitotane—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.0017	0.00234	CcSEcCtD
Mitotane—Rash—Sorafenib—thyroid cancer	0.00169	0.00233	CcSEcCtD
Mitotane—Dermatitis—Sorafenib—thyroid cancer	0.00169	0.00232	CcSEcCtD
Mitotane—Breast disorder—Doxorubicin—thyroid cancer	0.00168	0.00232	CcSEcCtD
Mitotane—Headache—Sorafenib—thyroid cancer	0.00168	0.00231	CcSEcCtD
Mitotane—Muscular weakness—Doxorubicin—thyroid cancer	0.00164	0.00226	CcSEcCtD
Mitotane—Neutropenia—Epirubicin—thyroid cancer	0.00163	0.00224	CcSEcCtD
Mitotane—Nausea—Sorafenib—thyroid cancer	0.00159	0.00219	CcSEcCtD
Mitotane—FDX1—Metabolism—HPGD—thyroid cancer	0.00157	0.0134	CbGpPWpGaD
Mitotane—Infestation NOS—Epirubicin—thyroid cancer	0.00155	0.00214	CcSEcCtD
Mitotane—Infestation—Epirubicin—thyroid cancer	0.00155	0.00214	CcSEcCtD
Mitotane—Drowsiness—Epirubicin—thyroid cancer	0.00155	0.00214	CcSEcCtD
Mitotane—Neutropenia—Doxorubicin—thyroid cancer	0.00151	0.00207	CcSEcCtD
Mitotane—Haematuria—Epirubicin—thyroid cancer	0.00148	0.00204	CcSEcCtD
Mitotane—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00147	0.00202	CcSEcCtD
Mitotane—Infestation NOS—Doxorubicin—thyroid cancer	0.00144	0.00198	CcSEcCtD
Mitotane—Infestation—Doxorubicin—thyroid cancer	0.00144	0.00198	CcSEcCtD
Mitotane—Drowsiness—Doxorubicin—thyroid cancer	0.00144	0.00198	CcSEcCtD
Mitotane—Hepatitis—Epirubicin—thyroid cancer	0.00139	0.00192	CcSEcCtD
Mitotane—Urinary tract disorder—Epirubicin—thyroid cancer	0.00138	0.00189	CcSEcCtD
Mitotane—Haematuria—Doxorubicin—thyroid cancer	0.00137	0.00189	CcSEcCtD
Mitotane—Connective tissue disorder—Epirubicin—thyroid cancer	0.00137	0.00189	CcSEcCtD
Mitotane—Urethral disorder—Epirubicin—thyroid cancer	0.00137	0.00188	CcSEcCtD
Mitotane—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00136	0.00187	CcSEcCtD
Mitotane—Visual impairment—Epirubicin—thyroid cancer	0.00134	0.00185	CcSEcCtD
Mitotane—Eye disorder—Epirubicin—thyroid cancer	0.0013	0.00179	CcSEcCtD
Mitotane—Flushing—Epirubicin—thyroid cancer	0.00129	0.00178	CcSEcCtD
Mitotane—Hepatitis—Doxorubicin—thyroid cancer	0.00129	0.00178	CcSEcCtD
Mitotane—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00127	0.00175	CcSEcCtD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.00127	0.0109	CbGpPWpGaD
Mitotane—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00127	0.00174	CcSEcCtD
Mitotane—Angiopathy—Epirubicin—thyroid cancer	0.00126	0.00174	CcSEcCtD
Mitotane—Urethral disorder—Doxorubicin—thyroid cancer	0.00126	0.00174	CcSEcCtD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00125	0.0108	CbGpPWpGaD
Mitotane—Visual impairment—Doxorubicin—thyroid cancer	0.00124	0.00171	CcSEcCtD
Mitotane—Mental disorder—Epirubicin—thyroid cancer	0.00122	0.00168	CcSEcCtD
Mitotane—Malnutrition—Epirubicin—thyroid cancer	0.00121	0.00167	CcSEcCtD
Mitotane—Eye disorder—Doxorubicin—thyroid cancer	0.00121	0.00166	CcSEcCtD
Mitotane—Flushing—Doxorubicin—thyroid cancer	0.0012	0.00165	CcSEcCtD
Mitotane—CYP11B1—Corticotropin-releasing hormone—BRAF—thyroid cancer	0.0012	0.0103	CbGpPWpGaD
Mitotane—Dysgeusia—Epirubicin—thyroid cancer	0.00119	0.00164	CcSEcCtD
Mitotane—CYP11B1—Biological oxidations—RXRA—thyroid cancer	0.00118	0.0101	CbGpPWpGaD
Mitotane—Angiopathy—Doxorubicin—thyroid cancer	0.00117	0.00161	CcSEcCtD
Mitotane—Vision blurred—Epirubicin—thyroid cancer	0.00114	0.00157	CcSEcCtD
Mitotane—Mental disorder—Doxorubicin—thyroid cancer	0.00113	0.00156	CcSEcCtD
Mitotane—Malnutrition—Doxorubicin—thyroid cancer	0.00112	0.00155	CcSEcCtD
Mitotane—Anaemia—Epirubicin—thyroid cancer	0.00112	0.00154	CcSEcCtD
Mitotane—Dysgeusia—Doxorubicin—thyroid cancer	0.0011	0.00151	CcSEcCtD
Mitotane—Vertigo—Epirubicin—thyroid cancer	0.00109	0.0015	CcSEcCtD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00107	0.0092	CbGpPWpGaD
Mitotane—Vision blurred—Doxorubicin—thyroid cancer	0.00106	0.00146	CcSEcCtD
Mitotane—Hypertension—Epirubicin—thyroid cancer	0.00105	0.00144	CcSEcCtD
Mitotane—Anaemia—Doxorubicin—thyroid cancer	0.00104	0.00143	CcSEcCtD
Mitotane—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00103	0.00141	CcSEcCtD
Mitotane—CYP11A1—Corticotropin-releasing hormone—BRAF—thyroid cancer	0.00102	0.00878	CbGpPWpGaD
Mitotane—CYP11A1—Biological oxidations—RXRA—thyroid cancer	0.00101	0.00866	CbGpPWpGaD
Mitotane—Vertigo—Doxorubicin—thyroid cancer	0.00101	0.00139	CcSEcCtD
Mitotane—Confusional state—Epirubicin—thyroid cancer	0.000998	0.00137	CcSEcCtD
Mitotane—Infection—Epirubicin—thyroid cancer	0.000984	0.00135	CcSEcCtD
Mitotane—Shock—Epirubicin—thyroid cancer	0.000974	0.00134	CcSEcCtD
Mitotane—Nervous system disorder—Epirubicin—thyroid cancer	0.000971	0.00134	CcSEcCtD
Mitotane—Thrombocytopenia—Epirubicin—thyroid cancer	0.000969	0.00133	CcSEcCtD
Mitotane—Hypertension—Doxorubicin—thyroid cancer	0.000969	0.00133	CcSEcCtD
Mitotane—Skin disorder—Epirubicin—thyroid cancer	0.000962	0.00132	CcSEcCtD
Mitotane—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000949	0.00131	CcSEcCtD
Mitotane—Anorexia—Epirubicin—thyroid cancer	0.000944	0.0013	CcSEcCtD
Mitotane—Hypotension—Epirubicin—thyroid cancer	0.000925	0.00127	CcSEcCtD
Mitotane—Confusional state—Doxorubicin—thyroid cancer	0.000924	0.00127	CcSEcCtD
Mitotane—Infection—Doxorubicin—thyroid cancer	0.00091	0.00125	CcSEcCtD
Mitotane—Shock—Doxorubicin—thyroid cancer	0.000901	0.00124	CcSEcCtD
Mitotane—FDX1—Metabolism—TPR—thyroid cancer	0.0009	0.00772	CbGpPWpGaD
Mitotane—Nervous system disorder—Doxorubicin—thyroid cancer	0.000898	0.00124	CcSEcCtD
Mitotane—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000897	0.00123	CcSEcCtD
Mitotane—Skin disorder—Doxorubicin—thyroid cancer	0.00089	0.00122	CcSEcCtD
Mitotane—Paraesthesia—Epirubicin—thyroid cancer	0.000889	0.00122	CcSEcCtD
Mitotane—FDX1—Metabolism—PRKAR1A—thyroid cancer	0.000885	0.0076	CbGpPWpGaD
Mitotane—Somnolence—Epirubicin—thyroid cancer	0.00088	0.00121	CcSEcCtD
Mitotane—Anorexia—Doxorubicin—thyroid cancer	0.000873	0.0012	CcSEcCtD
Mitotane—Dyspepsia—Epirubicin—thyroid cancer	0.000872	0.0012	CcSEcCtD
Mitotane—CYP11B1—Metabolism—MINPP1—thyroid cancer	0.000866	0.00744	CbGpPWpGaD
Mitotane—Decreased appetite—Epirubicin—thyroid cancer	0.000861	0.00118	CcSEcCtD
Mitotane—Hypotension—Doxorubicin—thyroid cancer	0.000856	0.00118	CcSEcCtD
Mitotane—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000855	0.00118	CcSEcCtD
Mitotane—Pain—Epirubicin—thyroid cancer	0.000847	0.00117	CcSEcCtD
Mitotane—Paraesthesia—Doxorubicin—thyroid cancer	0.000823	0.00113	CcSEcCtD
Mitotane—Feeling abnormal—Epirubicin—thyroid cancer	0.000816	0.00112	CcSEcCtD
Mitotane—Somnolence—Doxorubicin—thyroid cancer	0.000814	0.00112	CcSEcCtD
Mitotane—Dyspepsia—Doxorubicin—thyroid cancer	0.000806	0.00111	CcSEcCtD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000802	0.00689	CbGpPWpGaD
Mitotane—Decreased appetite—Doxorubicin—thyroid cancer	0.000796	0.0011	CcSEcCtD
Mitotane—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000791	0.00109	CcSEcCtD
Mitotane—Pain—Doxorubicin—thyroid cancer	0.000783	0.00108	CcSEcCtD
Mitotane—Body temperature increased—Epirubicin—thyroid cancer	0.000783	0.00108	CcSEcCtD
Mitotane—Feeling abnormal—Doxorubicin—thyroid cancer	0.000755	0.00104	CcSEcCtD
Mitotane—CYP11A1—Metabolism—MINPP1—thyroid cancer	0.000741	0.00636	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—NDUFA13—thyroid cancer	0.000736	0.00632	CbGpPWpGaD
Mitotane—Hypersensitivity—Epirubicin—thyroid cancer	0.000729	0.001	CcSEcCtD
Mitotane—Body temperature increased—Doxorubicin—thyroid cancer	0.000724	0.000997	CcSEcCtD
Mitotane—Asthenia—Epirubicin—thyroid cancer	0.00071	0.000978	CcSEcCtD
Mitotane—CYP11B1—Metabolism—CHST14—thyroid cancer	0.000692	0.00594	CbGpPWpGaD
Mitotane—Diarrhoea—Epirubicin—thyroid cancer	0.000677	0.000933	CcSEcCtD
Mitotane—Hypersensitivity—Doxorubicin—thyroid cancer	0.000675	0.000929	CcSEcCtD
Mitotane—FDX1—Metabolism—SLC5A5—thyroid cancer	0.000673	0.00578	CbGpPWpGaD
Mitotane—Asthenia—Doxorubicin—thyroid cancer	0.000657	0.000905	CcSEcCtD
Mitotane—Dizziness—Epirubicin—thyroid cancer	0.000655	0.000901	CcSEcCtD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000631	0.00542	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—NDUFA13—thyroid cancer	0.00063	0.00541	CbGpPWpGaD
Mitotane—Vomiting—Epirubicin—thyroid cancer	0.000629	0.000867	CcSEcCtD
Mitotane—Diarrhoea—Doxorubicin—thyroid cancer	0.000627	0.000863	CcSEcCtD
Mitotane—Rash—Epirubicin—thyroid cancer	0.000624	0.000859	CcSEcCtD
Mitotane—Dermatitis—Epirubicin—thyroid cancer	0.000624	0.000859	CcSEcCtD
Mitotane—Headache—Epirubicin—thyroid cancer	0.00062	0.000854	CcSEcCtD
Mitotane—Dizziness—Doxorubicin—thyroid cancer	0.000606	0.000834	CcSEcCtD
Mitotane—CYP11A1—Metabolism—CHST14—thyroid cancer	0.000592	0.00509	CbGpPWpGaD
Mitotane—Nausea—Epirubicin—thyroid cancer	0.000588	0.00081	CcSEcCtD
Mitotane—Vomiting—Doxorubicin—thyroid cancer	0.000582	0.000802	CcSEcCtD
Mitotane—Rash—Doxorubicin—thyroid cancer	0.000578	0.000795	CcSEcCtD
Mitotane—Dermatitis—Doxorubicin—thyroid cancer	0.000577	0.000794	CcSEcCtD
Mitotane—Headache—Doxorubicin—thyroid cancer	0.000574	0.00079	CcSEcCtD
Mitotane—FDX1—Metabolism—RXRA—thyroid cancer	0.000566	0.00486	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—HPGD—thyroid cancer	0.000558	0.00479	CbGpPWpGaD
Mitotane—FDX1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.00055	0.00473	CbGpPWpGaD
Mitotane—Nausea—Doxorubicin—thyroid cancer	0.000544	0.000749	CcSEcCtD
Mitotane—CYP11B1—Corticotropin-releasing hormone—AKT1—thyroid cancer	0.000485	0.00417	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—HPGD—thyroid cancer	0.000477	0.0041	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000453	0.00389	CbGpPWpGaD
Mitotane—CYP11A1—Corticotropin-releasing hormone—AKT1—thyroid cancer	0.000415	0.00357	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000387	0.00332	CbGpPWpGaD
Mitotane—FDX1—Metabolism—PPARG—thyroid cancer	0.000357	0.00307	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—TPR—thyroid cancer	0.000321	0.00275	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—PRKAR1A—thyroid cancer	0.000315	0.00271	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000286	0.00245	CbGpPWpGaD
Mitotane—FDX1—Metabolism—PTGS2—thyroid cancer	0.000281	0.00241	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—TPR—thyroid cancer	0.000274	0.00235	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—PRKAR1A—thyroid cancer	0.00027	0.00232	CbGpPWpGaD
Mitotane—FDX1—Metabolism—PTEN—thyroid cancer	0.000245	0.0021	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000245	0.0021	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—SLC5A5—thyroid cancer	0.00024	0.00206	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000225	0.00193	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—SLC5A5—thyroid cancer	0.000205	0.00176	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—RXRA—thyroid cancer	0.000202	0.00173	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000196	0.00168	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000192	0.00165	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—RXRA—thyroid cancer	0.000172	0.00148	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000168	0.00144	CbGpPWpGaD
Mitotane—FDX1—Metabolism—AKT1—thyroid cancer	0.000141	0.00121	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—PPARG—thyroid cancer	0.000127	0.00109	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—PPARG—thyroid cancer	0.000109	0.000935	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—PTGS2—thyroid cancer	0.0001	0.00086	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—PTEN—thyroid cancer	8.73e-05	0.00075	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—PTGS2—thyroid cancer	8.57e-05	0.000735	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—PTEN—thyroid cancer	7.47e-05	0.000641	CbGpPWpGaD
Mitotane—CYP11B1—Metabolism—AKT1—thyroid cancer	5.03e-05	0.000432	CbGpPWpGaD
Mitotane—CYP11A1—Metabolism—AKT1—thyroid cancer	4.31e-05	0.00037	CbGpPWpGaD
